Tysabri vs Stelara for Crohn's Disease: How They Compare

Tysabri and Stelara take very different mechanistic approaches to moderate-to-severe Crohn's disease. Stelara (ustekinumab) is an IL-12/23 biologic that is widely prescribed for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. Both drugs are often considered in patients with complex treatment histories who have failed anti-TNFs or other options. This guide walks through the tysabri vs stelara crohn's comparison.

Integrin vs IL-12/23 Mechanism

Tysabri binds alpha-4 integrin, blocking lymphocyte trafficking to both gut and brain tissue. Stelara binds the p40 subunit shared by IL-12 and IL-23, blocking both cytokines. IL-23 is a central driver of Th17-mediated inflammation in Crohn's. The natalizumab vs ustekinumab distinction shapes both safety and efficacy, with Tysabri's broader integrin mechanism creating PML risk and Stelara's IL-12/23 blockade producing a cleaner systemic profile.

Crohn's Efficacy

Tysabri's Crohn's efficacy rests on ENACT-1, ENACT-2, and ENCORE. Stelara's Crohn's efficacy rests on UNITI-1 (biologic-experienced), UNITI-2 (biologic-naive), and IM-UNITI (maintenance). Both drugs have shown meaningful response in biologic-experienced populations. No head-to-head trial has directly compared Tysabri with Stelara in Crohn's. Indirect comparisons suggest similar efficacy in biologic-experienced patients, though Stelara's favorable safety profile typically drives it to be tried before Tysabri in most treatment algorithms.

PML Risk and TOUCH Program

Tysabri carries a black-box warning for PML, a rare but often fatal demyelinating brain disease caused by JC virus reactivation. The TOUCH program requires enrollment, JC virus antibody testing, routine monitoring, and prescriber/pharmacy/infusion center certification. Most gastroenterologists reserve Tysabri for Crohn's patients who have failed multiple other biologic classes and who test negative for JC virus antibodies. Stelara has no such restricted access program.

Stelara Safety Profile

Stelara's long-term safety data from more than a decade of post-marketing experience in psoriasis, Crohn's, and UC shows low rates of serious infection. Stelara is considered one of the safest biologic options for IBD. For tysabri vs stelara side effects, Stelara is clearly preferred for patients with infection concerns, cancer history, or complex comorbidities.

Biologic Failure Crohn's

For Crohn's patients who have failed one or more biologics, Stelara is typically tried before Tysabri because of its favorable safety profile. Stelara has established data in anti-TNF experienced patients through UNITI-1. Tysabri is typically reserved for patients who have failed Stelara, anti-TNFs, and other biologic classes. For biologic failure crohn's decision-making, the typical sequence is anti-TNF → Stelara or IL-23 p19 → gut-selective Entyvio, with Tysabri considered only in refractory cases.

Administration and Dosing

Tysabri is administered as a 300 mg IV infusion every 4 weeks at a TOUCH-certified infusion center, per Biogen's prescribing information. Stelara starts with weight-based IV induction at week 0 (dose 260-520 mg based on weight), followed by subcutaneous maintenance of 90 mg every 8 weeks, per Janssen's Stelara prescribing information. For Crohn's patients comparing administration, Stelara requires one IV infusion before transitioning to SC maintenance every 8 weeks. Tysabri requires lifelong monthly IV infusions at a TOUCH-certified center.

When Tysabri Might Be Considered

For Crohn's patients who have failed multiple biologic classes including Stelara, Tysabri may be considered, particularly in patients who test negative for JC virus antibodies (indicating lower PML risk). This is a narrow population, and shared decision-making with a gastroenterologist experienced in refractory Crohn's is essential.

Biosimilar Availability

Stelara's patent expired in 2023, and ustekinumab biosimilars launched in the US market beginning in 2025, which may lower acquisition costs for Stelara going forward. Tysabri has a biosimilar (Tyruko) approved in 2023, though real-world utilization in IBD remains low given TOUCH program requirements apply equally to biosimilars.

Practical Access

Stelara can be administered at a variety of infusion centers for induction, and SC maintenance can be self-administered at home. Tysabri requires infusion at a TOUCH-certified center. For patients with complex schedules or geographic barriers, Stelara's accessibility is a practical advantage.

Choosing With Your GI

For a Crohn's patient deciding between Tysabri and Stelara, Stelara is preferred for most patients because of its established role, favorable safety profile, SC maintenance convenience, biosimilar cost options, and absence of TOUCH program restrictions. Tysabri is a niche option reserved for patients who have exhausted other biologic classes including Stelara and who test JC virus antibody negative. If you are considering Tysabri, ask your GI about JC virus antibody status, prior treatment history, and the specific risk-benefit rationale. A log of stool frequency, urgency, abdominal pain, and any new neurological symptoms between visits is particularly important for patients on Tysabri.